康泰医学(300869) - 2023 Q2 - 季度财报

Exchange Rate Risks and Mitigation Strategies - The company faces exchange rate risks due to its overseas sales primarily settled in USD, which could impact product competitiveness and financial performance[132] - The company plans to mitigate exchange rate risks by adjusting the ratio of domestic to international sales and using financial instruments like hedging[132] Talent and Competitive Risks - Intense competition in the medical device industry poses a risk of talent loss, which could slow product development and lead to technology leaks[133] Fundraising and Market Risks - The company has conducted market research and feasibility analysis for its fundraising projects but acknowledges risks related to policy changes, market conditions, and management[134] Corporate Governance and Shareholder Meetings - The company held its 2022 Annual General Meeting with a 65.49% investor participation rate on May 19, 2023[140] - Several board members and supervisors, including the Chairman of the Board of Supervisors, completed their terms and were replaced on May 19, 2023[141] Dividend and Capital Distribution Policies - The company does not plan to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital in the first half of the year[142] Social Responsibility and Public Health - The company emphasizes its commitment to social responsibility, focusing on providing high-quality medical devices and contributing to public health[146]